Outpatient Worsening Heart Failure in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial

Marianna Fontana; Mathew S Maurer; Julian D Gillmore; Shaun Bender; Emre Aldinc; Satish A Eraly; Patrick Y Jay; Scott D Solomon

doi:10.1016/j.jacc.2024.11.015

Outpatient Worsening Heart Failure in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial

J Am Coll Cardiol. 2024 Nov 9:S0735-1097(24)10464-0. doi: 10.1016/j.jacc.2024.11.015. Online ahead of print.

Authors

Marianna Fontana¹, Mathew S Maurer², Julian D Gillmore¹, Shaun Bender³, Emre Aldinc³, Satish A Eraly³, Patrick Y Jay³, Scott D Solomon⁴

Affiliations

¹ National Amyloidosis Centre, UCL, Division of Medicine, Royal Free Hospital, London, UK.
² Columbia University Irving Medical Center, New York, New York, USA.
³ Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
⁴ Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA. Electronic address: SSOLOMON@BWH.HARVARD.EDU.

PMID: 39566871
DOI: 10.1016/j.jacc.2024.11.015

Abstract

Background: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a fatal disease, caused by misfolded transthyretin depositing as amyloid fibrils in the heart. Because disease progression is common, practical and sensitive methods are needed to monitor patients and optimize treatment decisions. Outpatient worsening heart failure (HF) (oral loop diuretic intensification or initiation) is simple to assess and has been shown to be prognostic of mortality in patients with ATTR-CM.

Objectives: We aimed to assess the clinical and prognostic significance of and the effect of vutrisiran treatment on outpatient worsening HF in patients with ATTR-CM from the HELIOS-B trial.

Methods: Associations between outpatient worsening HF and a composite of all-cause mortality and recurrent cardiovascular (CV) events (CV hospitalizations and urgent HF visits), all-cause mortality, and other disease progression-related endpoints were evaluated. The impact of vutrisiran over 36 months on outpatient worsening HF and an expanded composite of all-cause mortality, recurrent CV events, and outpatient worsening HF was also assessed.

Results: Overall, 321 patients (49.1%) had ≥1 outpatient worsening HF, 245 (37.5%) had ≥1 CV event(s), and 120 (18.3%) died; 237 patients (36.2%) had no events. Patients with outpatient worsening HF had an increased risk of all-cause mortality and CV events (hazard ratio [HR]: 2.58; 95% confidence interval [CI]: 2.04-3.27) and all-cause mortality (HR: 2.45; 95% CI: 1.70-3.52), as well as a greater deterioration in 6-minute walk test distance and Kansas City Cardiomyopathy Questionnaire-Overall Summary score, and a greater increase in N-terminal prohormone of B-type natriuretic peptide. In recurrent event analyses over the double-blind period, vutrisiran versus placebo reduced the rate of outpatient worsening HF (relative rate ratio: 0.66; 95% CI: 0.56-0.78). Vutrisiran also reduced the risk of the composite of all-cause mortality, CV events, and outpatient worsening HF versus placebo (HR: 0.69; 95% CI: 0.57-0.83).

Conclusions: Outpatient worsening HF was frequent in patients with ATTR-CM in HELIOS-B, and was associated with increased mortality, and reduced by vutrisiran.

Keywords: RNAi; cardiomyopathy; diuretic; heart failure; transthyretin amyloidosis.